Author

J. Vowles

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cell signaling & trafficking· 1 Assay:proteomics· 1 Approach:statistical model· 1 Research Focus:variant calling· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

S. A. Cowley· 2 shared W. S. James· 2 shared A. Baca· 1 shared A. T. Hanrath· 1 shared A. Talasaz· 1 shared C. Browne· 1 shared C. F. Hatton· 1 shared C. J. A. Duncan· 1 shared

Activity by Year

2017-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

S. A. Cowley

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Type I interferons govern Zika virus resistance of human macrophages and microglia

A. T. Hanrath, C. F. Hatton, F. Gothe, C. Browne, J. Vowles, P. Leary, S. J. Cockell, S. A. Cowley, W. S. James, S. Hambleton, C. J. A. Duncan

This study shows that type I interferons restrict Zika virus replication in macrophages and microglia, and their suppression increases viral replication and cell damage.

bioRxiv · Mar 9, 2022 · PreprintCell Biology

LRRK2 is recruited to phagosomes and co-recruits Rab8 and Rab10 in human pluripotent stem cell-derived macrophages

H. Lee, R. Flynn, I. Sharma, P. J. Carling, F. J. Nicholls, M. Stegmann, J. Vowles, R. Wade-Martins, W. S. James, S. A. Cowley

This study shows LRRK2 is recruited to maturing phagosomes and required for Rab8a and Rab10 recruitment in human macrophages.

bioRxiv · Sep 25, 2019Immunology

The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients

O. Zill, K. Banks, S. Fairclough, S. Mortimer, J. Vowles, R. Mokhtari, D. R. Gandara, P. C. Mack, J. Odegaard, R. Nagy, A. Baca, H. Eltoukhy, D. Chudova, R. Lanman, A. Talasaz

This study analyzes cfDNA from 21,807 cancer patients to identify actionable genomic alterations and their relationship to treatment and tumor heterogeneity.

bioRxiv · Dec 12, 2017Cancer Biology